Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
Open accessThe DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Abstract
Immunotherapy is a clinically validated treatment for many cancers to boost the immune system against tumor growth and dissemination. Several strategies are used to harness immune cells: monoclonal antibodies against tumor antigens, immune checkpoint inhibitors, vaccination, adoptive cell therapies (e.g., CAR-T cells) and cytokine administration. In the last decades, it is emerging that the chemokine system represents a potential target for immunotherapy. Chemokines, a large family of cytokines with chemotactic activity, and their cognate receptors are expressed by both cancer and stromal cells. Their altered expression in malignancies dictates leukocyte recruitment and activation, angiogenesis, cancer cell proliferation, and metastasis in all the stages of the disease. Here, we review first attempts to inhibit the chemokine system in cancer as a monotherapy or in combination with canonical or immuno-mediated therapies. We also provide recent findings about the role in cancer of atypical chemokine receptors that could become future targets for immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer
Wang, J., Shiozawa, Y., Wang, J., Wang, Y., Jung, Y., Pienta, K. J., Mehra, R., Loberg, R., & Taichman, R. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707465200 · Cited by 457
RetractedMantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 1×
“Inflammation is an essential component of the tumor microenvironment and one of the hallmarks of cancer (1, 2).”
BackgroundCancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 2×
“AMD3100 + anti-PD-L1 Pancreatic cancer (89) AMD3100 Recurrent GBM NCI2012-00149;”
BackgroundChemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
Griffith, J. W., Sokol, C. L., & Luster, A. D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120145 · Cited by 2,059
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Teicher, B. A., & Fricker, S. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2329 · Cited by 1,449
Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943
Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 845
Nywening, T. M., Wang-Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R. K., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 807
Cited by
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Self-citationCombination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 548
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers
Li, Y., Jiang, T., Zhou, W., Li, J., Li, X., Wang, Q., Jin, X., Yin, J., Chen, L., Zhang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14802-2 · Cited by 414
McSweeney, K. R., Gadanec, L. K., Qaradakhi, T., Ali, B. A., Zulli, A., & Apostolopoulos, V. (2021) · Cancers · doi:10.3390/cancers13071572 · Cited by 363
Colorectal liver metastasis: molecular mechanism and interventional therapy
Zhou, H., Liu, Z., Wang, Y., Wen, X., Amador, E. H., Yuan, L., Ran, X., Xiong, L., Ran, Y., Chen, W., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00922-2 · Cited by 298
Multiple Roles for Chemokines in Neutrophil Biology
Capucetti, A., Albano, F., & Bonecchi, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01259 · Cited by 285
Self-citationHow chemokines organize the tumour microenvironment
Mempel, T. R., Lill, J. K., & Altenburger, L. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00635-w · Cited by 281
Immunomodulation by radiotherapy in tumour control and normal tissue toxicity
Cytlak, U. M., Dyer, D. P., Honeychurch, J., Williams, K. J., Travis, M. A., & Illidge, T. M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00568-1 · Cited by 258
Cell membrane coated-nanoparticles for cancer immunotherapy
Zeng, Y., Li, S., Zhang, S., Wang, L., Yuan, H., & Hu, F. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.023 · Cited by 238
Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential
Jiang, B.-C., Liu, T., & Gao, Y.-J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107581 · Cited by 237
Chemokine alterations in bipolar disorder: A systematic review and meta-analysis
Misiak, B., Bartoli, F., Carrà, G., Małecka, M., Samochowiec, J., Jarosz, K., Banik, A., & Stańczykiewicz, B. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.013 · Cited by 102
BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy
Samanta, D., Huang, T. Y.-T., Shah, R., Yang, Y., Pan, F., & Semenza, G. L. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108073 · Cited by 49
Bissonnette, R. P., Cesario, R. M., Goodenow, B., Shojaei, F., & Gillings, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08702-x · Cited by 24
Sakai, S. A., Oyoshi, H., Nakamura, M., Taki, T., Nomura, K., Hojo, H., Hirata, H., Motegi, A., Nakamura, Y., Zenkoh, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03088-0 · Cited by 15
Regulatory T Cells Keep Pancreatic Cancer at Bay
Aykut, B., Chen, R., & Miller, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0002 · Cited by 11
Metadata
- Authors
- Mollica Poeta, V., Massara, M., Capucetti, A., & Bonecchi, R.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-03-06
- Volume
- 10
- Pages
- 379-379
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2918297277
- Cited by
- 583
- References
- 125
- FWCI
- 29.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.